Global Livestock Vaccines Market

The Global Livestock Vaccines Market Size is foreseen to grow from USD 6.10 Billion in 2025 and is govern to reach around USD 12.1 Billion by 2035. According to Decision Advisors, a detailed research report on the global livestock vaccines market is boosted by acceleration of vaccination campaigns, accounting for nearly upto the 62-64% share of the total share worldwide. Zoetis Inc. is the prime player in the market with approximately USD 2.85 Billion in annual turnover and a 40-45% market share, positioning it as the primary driver of the global livestock vaccines market.

 Market Snapshot

• Global Livestock Vaccines Market Size (2025): USD 6.10 Billion
• Projected Global Livestock Vaccines Market Size (2035): USD 12.1 Billion
• Global Livestock Vaccines Market Compound Annual Growth Rate (CAGR): 7.09%
• Largest Regional Market: North America
• Fastest Growing Region: Asia Pacific
• 2^nd Largest Region: Europe
• Base Year: 2025
• Historical Period: 2021–2024
• Forecast Period: 2026–2035

Market Overview/ Introduction

The Global Livestock Vaccines Market is the backbone of modern farming, focused on creating and delivering the medicine needed to keep farm animals healthy and immune to infectious diseases. Beyond just treating animals, this industry is a critical line of defense for humans it helps prevent zoonotic diseases from jumping from animals to people while ensuring the world has a steady, safe supply of meat and dairy.This growth is being governs by a world population and the steady battle against resilient outbreaks like Foot and Mouth Disease. To keep up, big firms like Zoetis and Merck are moving away from old-school methods and spending resources into high-tech DNA-based vaccines that are safer and more effective. At the same time, governments are stepping in with huge support, for example, India has committed roughly $460 million to a nationwide push to wipe out livestock diseases by 2030. As we look to the future, the industry is moving toward cutting-edge mRNA technology—the same tech used in recent human vaccines to respond faster to new threats. While North America is the current leader, the real excitement is in the Asia-Pacific region, where rapid growth and a massive increase in farming are making it the next big frontier for animal health.

• The Food and Agriculture Organisation (FAO) collaborated with the Government of Sudan to launch a nationwide vaccination campaign targeting 9.4 million livestock, aimed at controlling transboundary diseases and protecting the livelihoods of over 3 million pastoralists.

• The Arab Authority for Agricultural Investment and Development (AAAID) partnered with MEVAC and multiple government stakeholders to expand the largest veterinary vaccine manufacturing facility, with a capacity of over 12 billion doses annually, strengthening regional supply.

• Egypt collaborated with Uganda’s National Agricultural Research Organisation (NARO) to establish local Foot-and-Mouth Disease (FMD) vaccine production, including technology transfer and training of scientists, supporting long-term self-sufficiency in livestock vaccination.

• Egypt’s Ministry of Agriculture signed a €4 million partnership agreement with FAO to enhance livestock development, improve animal health systems, and combat antimicrobial resistance through coordinated vaccination and disease control strategies.

Notable Insights: -

1. North America is anticipated to hold the largest share, approximately 37% of the global livestock vaccines market over the predicted timeframe.
2. Asia Pacific is expected to grow at the fastest CAGR in the global livestock vaccines market during the forecast period, with growth rates estimated at around 10% CAGR.
3. By product type, the live attenuated vaccines segment dominated the market in 2025 with approximately 40% share, and is projected to grow at a substantial CAGR during the forecast period.
4. By end user, the livestock farms segment dominated the market in 2025 with approximately 65% share, and is projected to grow at a substantial CAGR during the forecast period.
5. The compound annual growth rate of the global livestock vaccines market is 7.09%.
6. The market is likely to achieve a valuation of USD 12.1 Billion by 2035.

What is the role of technology in grooming the market?

Technology plays a crucial role in shaping the livestock vaccines market by improving vaccine development, delivery, and disease monitoring. Advanced technologies such as recombinant DNA and mRNA platforms enable faster and more effective vaccine production, while digital tools like AI and data analytics help track disease outbreaks and optimize vaccination strategies. For example, companies like Zoetis use genomic and data-driven platforms to develop targeted vaccines for cattle diseases, improving herd health and productivity. Additionally, smart farming systems and IoT-based animal monitoring allow early detection of infections, ensuring timely vaccination and reducing economic losses for farmers.

Market Drivers

The growth of the livestock vaccine market is really being propelled by our global appetite for meat and dairy. As farming becomes more massive to keep up with this demand, keeping herds healthy is no longer just a choice, it’s a necessity. A major driving force is the steady threat of outbreaks like Avian Flu or Foot and Mouth Disease, which can devastate a farmer’s livelihood overnight and, in some cases, even jump to humans. To avoid this, the industry is going away from overusing antibiotics and trending toward prevention, using smarter technology like mRNA and recombinant vaccines that are safer and react faster to new viruses. Governments are also stepping up in a big way, in countries like India and China, state-funded programs are making vaccines much more affordable and accessible for rural farmers. Essentially, the combination of better tech, stronger government backing, and a global push for cleaner food production is making vaccination the new standard in modern farming.

Restrain

The livestock vaccines market faces several restraints, including high development and regulatory costs, which make vaccines expensive and time-consuming to bring to market. Additionally, maintaining cold chain logistics for storage and transportation remains a major challenge, especially in rural and developing regions.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global livestock vaccines market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

Top Companies in the Global Livestock Vaccines Market

1. Zoetis
2. Merck & Co, Inc.
3. Boehringer Ingelheim Animal Health
4. Elanco Animal Health Inc.
5. Ceva Sante Animale
6. Virbac S.A.
7. HIPRA, S.A.
8. Phibro Animal Health Corporation
9. Vetoquinol S.A.
10. IDT Biologika GmbH

Government Initiatives

Study on the Supply, Demand, Distribution, and Market Environment of the Global Livestock Vaccines Market

The global livestock vaccines market reflects a balanced dynamic between supply, demand, distribution, and market environment, driven by rising livestock populations and disease outbreaks. On the demand side, increasing consumption of animal protein and food security concerns are boosting vaccine adoption, while supply is strengthened by advancements in biotechnology and growing manufacturing capacity. In terms of distribution, veterinary hospitals and clinics dominate channels, with emerging e-commerce platforms improving access in remote areas. The market environment is highly supportive, backed by government vaccination programs and biosecurity initiatives. Statistically, the market was valued at around USD 6.4-6.8 billion in 2024-2025 and is projected to reach over USD 12 billion by 2034, growing at a CAGR of about 7%, reflecting strong global expansion.

Price Analysis and Consumer Behaviour Analysis

Price analysis in the livestock vaccines market shows relatively higher pricing due to R&D and cold chain costs, with advanced vaccines (such as recombinant) costing 25% more than conventional ones. However, bulk procurement by large farms and government programs can reduce costs by 20% per dose. From a consumer behaviour perspective, over 67% of livestock farmers prioritise vaccine effectiveness and disease prevention over price, as vaccination can reduce disease-related losses by up to 45%. Additionally, increasing awareness and government initiatives have led to a steady rise in adoption, particularly among small and mid-scale farmers, supporting overall market growth.

Market Segmentation

The Global Livestock Vaccines Market share is classified into product type, route of administration, disease type, and end user.

• The live attenuated vaccines segment dominated the market in 2025 with approximately 40% share, and is projected to grow at a substantial CAGR during the forecast period.

Based on the product type, the global livestock vaccines market is divided into inactivated vaccines, live attenuated vaccines, recombinant vaccines, and DNA vaccines. Among these, the live attenuated vaccines segment dominated the market in 2025 with approximately 40% share, owing to their ability to provide strong and long-lasting immunity with fewer doses and lower cost. For instance, live vaccines are widely used in cattle and poultry for diseases such as Newcastle disease and bovine respiratory infections. Additionally, recent advancements in vaccine safety and stability (2023–2025) have improved adoption rates. Recombinant vaccines are expected to witness faster growth due to increasing focus on precision and safety.

• The intramuscular segment accounted for the largest share in 2025 with approximately 55%, and is anticipated to grow at a significant CAGR during the forecast period.

Based on the route of administration, the global livestock vaccines market is divided into intramuscular, subcutaneous, oral, and intranasal. Among these, the intramuscular segment accounted for the largest share in 2025 with approximately 55%, driven by its accuracy in dosage and effectiveness in generating an immune response across livestock species. For example, vaccines for foot-and-mouth disease and bovine respiratory diseases are commonly administered via the intramuscular route. Moreover, innovations such as needle-free delivery systems (introduced during 2023–2024) are enhancing efficiency and animal welfare. Oral and intranasal routes are gaining traction due to ease of mass administration.

• The foot-and-mouth disease (FMD) segment dominated the market in 2025 with approximately 30% share, and is projected to grow at a substantial CAGR during the forecast period.

Based on the disease type, the global livestock vaccines market is divided into foot-and-mouth disease, avian influenza, Newcastle disease, brucellosis, bovine respiratory disease, and others. Among these, the FMD segment dominated the market in 2025 with approximately 30% share, owing to its high transmissibility and severe economic impact on livestock industries globally. For instance, FMD outbreaks can lead to massive production losses and trade restrictions. Additionally, government-led vaccination campaigns and disease eradication programs (2023–2025) are significantly boosting demand. Avian influenza and Newcastle disease also hold notable shares due to frequent outbreaks in poultry.

• The livestock farms segment dominated the market in 2025 with approximately 65% share, and is projected to grow at a substantial CAGR during the forecast period.

Based on the end user, the global livestock vaccines market is divided into livestock farms, veterinary clinics, and research institutes. Among these, the livestock farms segment dominated the market in 2025 with approximately 65% share, due to large-scale vaccination practices aimed at disease prevention and productivity enhancement. For instance, commercial dairy and poultry farms implement routine vaccination schedules to minimize mortality and improve output. Furthermore, government-supported immunisation programs and increasing awareness among farmers (2023–2025) are driving adoption. Veterinary clinics and research institutes hold smaller shares but play a crucial role in diagnostics and vaccine development.

Strategies to Implement for Growth of the Market in Non-Leading Regions

To drive growth of the livestock vaccines market in non-leading regions, companies should focus on expanding awareness through farmer education programs and government collaborations to promote vaccination benefits. Strengthening distribution networks and cold chain infrastructure is essential to ensure vaccine accessibility in remote areas. Additionally, adopting cost-effective pricing strategies, such as subsidies and bulk supply models, can improve affordability for small-scale farmers. Leveraging mobile veterinary services and digital platforms for disease monitoring can further enhance vaccine adoption, while partnerships with local stakeholders can help tailor solutions to region-specific livestock health challenges.

Regional Segment Analysis of the Global Livestock Vaccines Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share, approximately 37% of the global livestock vaccines market over the predicted timeframe.

North America is anticipated to hold the largest share, approximately 37% of the global livestock vaccines market over the predicted timeframe. The region dominates due to its advanced livestock infrastructure and high adoption of preventive healthcare practices, particularly in the United States and Canada, where vaccination coverage exceeds 87% in commercial farms. Additionally, the U.S. has over 90 million cattle and 70+ million swine, creating strong and consistent vaccine demand. A key recent development includes major animal health companies expanding biologics manufacturing capacities between 2023–2025, increasing production output by nearly 27%. Strict regulations on antibiotic use are also pushing farmers toward vaccination-based disease prevention, further strengthening market dominance

Asia Pacific is expected to grow at the fastest CAGR in the global livestock vaccines market during the forecast period, with growth rates estimated at around 10% CAGR.

Asia Pacific is expected to grow at the fastest CAGR in the global livestock vaccines market during the forecast period, with growth rates estimated at around 10% CAGR. The region has the largest livestock population globally, including over 400 million cattle and 350+ million pigs, with China and India being key contributors. Growth is driven by increasing meat consumption, frequent disease outbreaks such as Foot-and-Mouth Disease (FMD) and Avian Influenza, and rising government vaccination initiatives. For instance, countries like India and China have implemented large-scale immunization programs targeting 75% livestock coverage by 2025-2027, significantly boosting vaccine adoption. Additionally, expanding commercial farming and rising investments in veterinary infrastructure are accelerating market growth.

Europe is the second largest region in the global livestock vaccines market during the forecast period, holding approximately 27% share.

Europe is the second largest region in the global livestock vaccines market during the forecast period, holding approximately 27% share, supported by a livestock population exceeding 300 million animals across major countries. The region benefits from stringent animal health regulations and well-established vaccination programs, with farms typically administering 4–6 vaccines per production cycle. Countries such as Germany, France, and Spain lead the market due to strong dairy and meat industries. A recent development includes continued enforcement of EU animal health laws (2023–2025), promoting preventive vaccination and biosecurity measures. Additionally, increasing focus on reducing antibiotic usage has further strengthened vaccine adoption across the region.

Future Market Trends in the Global Livestock Vaccines Market: -

1. Adoption of advanced vaccine technologies is emerging as a key trend in the Global Livestock Vaccines Market.
   The market is witnessing rapid adoption of advanced technologies such as recombinant, DNA, and mRNA-based vaccines, which offer higher efficacy, safety, and faster production timelines. These next-generation vaccines are gaining traction due to their ability to target specific pathogens and reduce side effects. For instance, recombinant vaccines are increasingly used for diseases like avian influenza and bovine respiratory infections.
    
2. Rising focus on preventive healthcare and reduction of antibiotic usage is a major market trend.
   There is a global shift from treatment-based approaches to preventive vaccination due to increasing concerns over antimicrobial resistance. Governments and regulatory bodies are promoting vaccination programs to reduce dependency on antibiotics in livestock farming. For example, vaccination now accounts for a significant portion of disease prevention strategies, with over 45% of animal healthcare spending focused on prevention. This trend is further supported by strict regulations in developed regions and increasing awareness among farmers worldwide.
    
3. Expansion of vaccination programs in emerging economies is driving future market growth.
   Emerging regions such as Asia-Pacific, Latin America, and Africa are experiencing rapid growth due to increasing livestock populations and government-led immunisation initiatives. Large-scale vaccination campaigns and improving veterinary infrastructure are boosting adoption rates. For instance, livestock accounts for over 57% of total vaccine demand globally, highlighting its critical role in food security and farm productivity. Additionally, rising protein consumption and frequent disease outbreaks are accelerating vaccine demand in these regions.

Recent Development

• In April 2026, The Red Meat Industry Services (RMIS) launched new features on its traceability platform to support livestock management during the ongoing foot-and-mouth disease (FMD) outbreak in South Africa.

• In April 2026, the Sindh government launched a province-wide Pre-Monsoon Livestock Vaccination Program 2026-27 to protect animals from seasonal diseases ahead of the monsoon. The campaign, inaugurated in Karachi, ensured adequate vaccine supply and readiness of veterinary facilities across the province.

• In March 2026, Vihiga County launched an e-voucher livestock vaccination and identification programme to control major diseases such as Foot-and-Mouth Disease (FMD), anthrax, and lumpy skin disease while improving traceability of animal products. The initiative enabled digital registration and tracking of livestock, with approximately 11,000 cattle vaccinated out of a target of 80,000 animals at the time of launch

• In February 2026, the Food and Agriculture Organisation (FAO) launched a nationwide livestock vaccination campaign in Sudan to protect approximately 9.4 million animals against major diseases. The initiative focused on safeguarding livelihoods, improving food security, and preventing disease outbreaks amid ongoing challenges in the region.

• In January 2026, Egypt’s Ministry of Agriculture and Land Reclamation launched an exceptional nationwide livestock vaccination campaign targeting Foot-and-Mouth Disease (FMD) and Rift Valley Fever (RVF) across all governorates.

How are recent developments helping the Market?

Recent developments are significantly accelerating the growth of the livestock vaccines market by improving accessibility, efficiency, and innovation. The launch of advanced vaccines (such as multivalent and recombinant types) with efficacy rates above 90–96% has enhanced disease protection and farmer confidence. Additionally, innovations like thermostable vaccines capable of remaining effective at 30°C for up to 28 days are expanding reach in low-infrastructure regions. Government-led vaccination campaigns are also playing a major role; for instance, large-scale programs in countries like India and France are targeting approximately 83% livestock coverage, significantly boosting adoption rates. Furthermore, investments in manufacturing and technology, including capacity expansions producing billions of doses annually, are strengthening supply and supporting a steady market growth trajectory.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decision Advisors has segmented the global livestock vaccines market based on the below-mentioned segments: 

Global Livestock Vaccines Market, By Product Type

• Inactivated Vaccines
• Live Attenuated Vaccines
• Recombinant Vaccines
• DNA Vaccines

Global Livestock Vaccines Market, By Route of Administration

• Intramuscular Injection
• subcutaneous
• Oral
• Intranasal

Global Livestock Vaccines Market, By Disease Type

• Foot-and-Mouth Disease (FMD)
• Avian Influenza
• Newcastle Disease
• Brucellosis
• Bovine Respiratory Disease
• Others

Global Livestock Vaccines Market, By End User

• Livestock Farms
• Veterinary Clinics
• Research Institutes

Global Livestock Vaccines Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

Frequently Asked Questions (FAQ)

1. What is the average duration of immunity provided by livestock vaccines?

The duration varies by vaccine type and disease, typically ranging from 6 months to 2 years, depending on booster requirements and animal species.

2. How do cold chain failures impact vaccine effectiveness in livestock?

Breaks in the cold chain can reduce vaccine potency by 25%, leading to lower immunity and increased risk of disease outbreaks.

3. What role do private-public partnerships play in livestock vaccination programs?

Collaborations between governments and private companies help expand vaccine reach, improve funding, and enhance large-scale immunisation efforts in developing regions.

4. How is climate change influencing livestock vaccine demand?

Changing climate conditions are increasing the spread of vector-borne and infectious diseases, thereby boosting the need for new and more adaptive vaccines.

5. What are the challenges in developing multivalent livestock vaccines?

Key challenges include antigen compatibility, maintaining efficacy across multiple diseases, and higher development costs compared to single-disease vaccines.